



Scientific Journal of Biology

Review Article

A Path Towards Eliminating Malaria: Drug Resistance A Major Roadblock? -

Sultan Ahmad^{1*}, Aqeel Ahmad² and Alkama Aziz³

¹Department of Microbiology, Shri Guru Ram Rai University, Dehradun, UK, India

²Department of Biotechnology, Jamia Millia Islamia, New Delhi, India

³Department of Botany, Ch. Charan Singh University, Meerut, UP, India

***Address for Correspondence:** Sultan Ahmad, Department of Microbiology, Shri Guru Ram Rai University, Dehradun, UK, India, Email: sultan.sgru@gmail.com

Submitted: 12 June 2020; **Approved:** 15 June 2020; **Published:** 17 June 2020

Cite this article: Ahmad S, Ahmad A, Aziz A. A Path Towards Eliminating Malaria: Drug Resistance A Major Roadblock? Sci J Biol. 2020;3(1): 001-009. <https://dx.doi.org/10.37871/sjb.id16>

Copyright: © 2020 Ahmad S, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Malaria has remained a life threatening disease in South-East Asia and Sub-Saharan Africa for decades. Many efforts have been spent on Global and regional surveillance of malaria burden. Over US\$ 2.7 billion was invested in malaria control and elimination globally in 2018. Insecticide-treated mosquito nets, rapid diagnostic tests and Artemisinin-based combination therapy are the three major pillars that malaria control and elimination currently relies on. Insecticide resistances as well as the anti-malarial drug resistance have emerged as the major road blocks in winning the war against malaria. Here we discuss in details the artemisinin chemotherapy, the resistance phenotypes associated with its widespread use and the molecular marker associated with artemisinin drug resistance. Specifically we discuss the surveillance of K13 genotypes as an essential step in tracking the ART drug resistance in malaria laden areas.

Keywords: Malaria; Plasmodium falciparum; Drug resistance; Artemisinin; K13

INTRODUCTION

Malaria has been the widespread and deadly parasitic infection caused by anopheline mosquitoes. It has become a global issue with 214 million recent cases and 438,000 deaths in 2015, mainly in the sub-Saharan African regions [1]. Over the last decade, malaria endemic regions have determined the dropping rate of malaria and shifting the focus from reducing to eliminating this life-threatening disease. It has been shown in the past that the decrease in malarial spread is achievable but very hard to sustain. The worldwide campaign to eradicate malaria has seriously failed due to the development of parasitic resistance to efficient antimalarial drugs and resistance of mosquito to insecticides. Now the global concern remains to introduce efficient drugs as a replacement of old and failed drugs [2,3].

Humans are affected by mainly four types of parasitic Plasmodium, but the falciparum species is notable for the majority of fatalities worldwide. Most of the studies are focused on the falciparum malaria, but more efforts should be directed towards the interpretation of other malaria species that would help us grasp the severity of malaria infections and design better intervention strategies [4,5]. At the same time, it is need of the hour to look for new vaccine candidates and design vaccines using novel strategies for malaria elimination [6-8]. It has been noted as the species, rendering dreadful malarial syndromes, has developed resistance to every antimalarial compound available. The use of antimalarial drugs like chloroquine, sulfadoxine and pyrimethamine has been extensively implemented in the past, and therefore, been misused. The parasites have developed resistance under selective pressure due to the preparation of antimalarial drugs on a broad scale [9,10]. When the parasites developed resistance to these antimalarial drugs in Southeast Asia, the P. falciparum endemic regions, mefloquine replaced other drugs, but soon resistance developed for this compound [11].

ARTEMISININ (ART) AND ARTEMISININ-BASED COMBINATION THERAPY (ACT)

Except one notable drug – Artemisinin (ART), resistance has been developed to all known antimalarial drugs. For centuries, Artemisinins have been used as traditional Chinese herbal medicine, derived from the plant, Artemisia annua and proved its efficacy against the life-threatening disease [12,13]. To prevent the emergence of resistance, artemisinins in combination with partner drugs, where other antimalarial drugs like chloroquine, sulfadoxine-pyrimethamine etc. are used as partners, are widely used. Due to the high potency of ART with slow-acting and less potent partner drugs, ACTs are known for higher parasite killing rate, lack of side effects and absence of resistance [14-16].

The ARTs being highly active against the asexual cycle of P. falciparum are capable of reducing the biomass of the malarial parasite along with short half-life (<1h) of ARTs in plasma, which necessitates the use of long-lasting partner drugs [17]. However, in spite of the significant usage, clinical ART resistance has not yet been demonstrated. Interestingly, the mode of action and inhibition of parasite growth regarding Artemisinin remains a curious case and a mystery to-date [18,19].

Derivatives of artemisinin that include dihydroartemisinin, artemether, arteether and artesunate and many others are called the first generation derivatives of ART and thus synthesized and used in treating malaria [20]. These derivatives are sesquiterpene lactones known for their high activity and rapid elimination of malarial parasites almost at all stages of development [16]. The suggested mechanism for ART activation is a Fe-hem mediated process cleaving the endoperoxide moiety of the ARTs and forming the Reactive Oxygen Species (ROS), which targets the nucleophilic groups in parasitic proteins and lipids. The artemisinin is known to covalently bind to 124 parasitic proteins, most of which are involved in biological metabolism essential for survival.

As recommended by WHO in 2001, Artemisinin-Based Combination Therapies (ACTs) are widely used as first-line multidrug-treatment resistant to P. falciparum [21,22]. In Southeastern Asia, artesunate-mefloquine has been effectively used for uncomplicated malaria caused by P. falciparum. The ACT being widely used and recommended is the dihydroartemisinin-piperquine in the Southeastern countries due to its promising efficacy [15]. White and others suggested that ART derivatives used along with antimalarial partner drugs could rapidly decrease the parasite density to a minimum, whereas keeping the optimum levels of the by longer activation of the drug components [23]. High efficacy of ACTs has been shown in the past in treating uncomplicated malaria in Asia and Africa; local data is not available in spite of the clear determination of antimalarial inefficiency during recent years [24-28].

The efficacy of ACTs was demonstrated in Afghanistan by one of the recent studies while conducting clinical trials utilizing a combination therapy of an ART derivative - Artesunate (AS) and Sulfadoxine-Pyrimethamine (SP). This study indicated the presence of drug resistant alleles which did not develop resistance against ACT treatment and hence, proved efficient for the intervention of malaria caused by P. falciparum [29].

EMERGENCE OF ART RESISTANCE

ART resistance phenotypes

Since a few years, ART resistance has emerged as a rising concern. The first report of ART resistance dates back to early 2000s near the

Thai-Cambodian border for which the results are still ambiguous. The signs of inefficacy of ACTs and artesunate monotherapy were clearly indicated in western Cambodian artesunate-resistant parasitic isolates [30]. According to WHO, the emergence of piperazine resistance in association to ART resistance and its aid in the selection of piperazine-resistant parasites are contemporarily unclear. It is, however, suggested that the piperazine resistance may have independently emerged due to the long life of piperazine and its prior use as monotherapy [31].

Various recent clinical, in vitro, transcriptomics and genomic studies in Southeast Asia have outlined the in vivo and in vitro ART-resistant phenotypes, determined its genetic basis, and have studied its clinical impact. Partial resistance is offered by the slow parasite clearance rates expressed only in the early-ring stages of the parasite [16]. A productive insight was provided by Duru and others in demonstrating the failure of ACTs, particularly dihydroartemisinin-piperazine in Cambodian isolates. All of the parasites in this study indicated the selection of parasite that were already resistant to artemisinin [32].

Clinical ART resistance

Clinical ART resistance can be defined as heightened half-life clearance of the parasite or the presence of detectable parasites on the 3rd day of ACT intervention. The parasitic half-life is highly associated with the in vitro and ex vivo Ring-Stage Assays (RSAs), which evaluate the endurance of the initial ring-stage parasites exposed to the 700nM dosage for 6 hours of the active metabolite of ART – the DHA (dihydroartemisinin) [17,33]. Nonetheless, the definition of clinical resistance is affected by various factors like host immunity, drug concentration in blood or activity of partner drug in the Artemisinin-Based Combination Therapy (ACT) [34]. No matter how impressive the gains of the ARTs and ACTs, the emergence of ART resistance has been noted in Greater Mekong Subregion (GMS) (Laos, Cambodia, Thailand, Vietnam, and Myanmar), which can lead to disastrous effects of malaria and an eventual spread to the African sub-continent. On the other hand, the risk of ART resistance in the malarial isolates is a greater problem as compared to the failure of the chloroquine and sulphadoxine-pyrimethamine resistance in various parts of the world due to its emerging resistance to falciparum malaria where other drugs have failed [17,22,35,36].

PARASITE CLEARANCE RATES

In order to elaborate the parasite clearance rates in Upper Myanmar despite the presence of ART resistance, another study revealed the therapeutic effect of another ART derivative - Dihydroartemisinin-Piperazine (DP). Tunet al. evaluated the median half-life of the parasite and determined it to be less than 5 h (4.7 h) due to the frequent evaluation of parasitaemia indicating an intermediate resistance as compared to other types of mutations in the relevant region. Also, the importance of relation of site with the delayed parasite clearance rate [33,37]. In a study by Amaratunga, et al. [38] the clearance of parasites took longer time than usual with a half-life of 11.28 h, indicating the widespread presence of ART-resistant phenotype outside Palan, Cambodia. It was also noted that some host factors accounted for the greater half-life while 40% half-life variation was due to parasite genetics. The identification of parasitic genetic cluster was found corroborated with the genetic basis for the ART resistance phenotype.

The delayed parasite clearance rate and resistance has also been noted due to the presence of resistant parasitic hypnozoite reservoirs

as observed in *P. falciparum* and *P. vivax* [39]. Other studies relate that the parasitic clearance half-life depends upon the susceptibility of the parasite to ART as well as on the developmental stage during ART treatment [17,36].

However, ART resistance remains undetected due to the inefficacy of resistance phenotypes in drug susceptibility assays in vitro. Some success has been achieved using advanced in vitro assays providing an insight into the parasitic susceptibility at developmental ring stages in the erythrocytes. Moreover, artemisinin-resistant phenotypes have been reported with reduced susceptibility to ART in a T₀ [3H] hypoxanthine assay during the development of ring stage, prolonged resistant (ring) stage and reduced trophozoite stage during development. The extended resistant stages and temporary compression of the most susceptible developmental stage are observed to be highly associated with ART resistance. The altered pattern of development in the parasitic cell cycle is due to the increasing practicality of the ART-resistant parasites during ART exposure at ring stages. Such phenotype in the assayed samples indicates shortened asexual life cycle of the parasite. These novel phenotypes provide an opportunity to detect the function of mutations linked to ART resistance and determining molecular markers linked to ART clinical resistance [17].

IDENTIFICATION OF K13 MUTATIONS AS A MOLECULAR MARKER OF ART RESISTANCE

In order to locate the gene responsible for artemisinin resistance, Genome-Wide Association Studies (GWAS) were carried out. The association of delayed clearance parasite rates with *P. falciparum* in Southeast Asia was indicated. After a Single-Nucleotide Polymorphism (SNP) assay, Takala-Harrison, et al. [40] via linkage-disequilibrium windows used as a marker of the decelerated clearance rate, recognized that four SNPs on chromosomes 10, 13, and 14 were related closely to the delayed parasite clearance. The SNPs on chromosome 10 and 13 indicated association with the genes involved in a DNA damage-tolerance pathway. These SNPs were later linked to the genes PF3D7_1343700 (Kelch 13) and PF3D7_1459600 (ENTH domain containing protein involved in clathrin mediated endocytosis) through an approach based on population genetics. The GWAS analysis has been utilized to highlight the heritable traits of clinical ART resistance and positive selection in geographical regions of ART resistance.

In recent studies, the K13-propeller mutations have been associated with artemisinin resistance in vivo and in vitro in Southeast Asia [36]. In relevance with the previous research, clinical resistance to ARTs have shown delayed parasite clearance rate, parasite clearance half-life of >5h, presence of heritable Kelch propeller mutations in the Pf3D7_1343700 domain, and its rapid spread, as noted in Southeast Asia [22,41]. It has now been proved via screening of the ART-resistant *P. falciparum* with K13 mutations that the presence of mutated *P. falciparum* has passed beyond the classical western Thai-Cambodia border [42].

As simple as it seems, the genetic basis for ART resistance is challenged by the introduction of molecular markers, which revealed a complex mystery that remains unsolved. With the objective to identify the genetic basis of ACT traits for adaptation, Cheeseman et al. [43] utilized a two-stage strategy to determine the genetic basis for underlying gene selection by comparing three geographical regions (Cambodia, Thailand and Laos). Screening and genotyping of 91

parasite clones determined Single-Nucleotide Polymorphisms (SNPs) and Copy Number Variations (CNVs). As a result, geographical differentiation and haplotype structure at 6969 SNPs determined a region of strong selection on chromosome 13 which corresponds to the decelerated parasite clearance rates.

Airey, et al. [36] conducted an expeditious study to analyze mutations in laboratory-adapted parasite clones selected for survival while receiving high ART dosage in vitro. The information yielded by such analysis can guide polymorphism analysis in ART-resistant parasitic samples from Cambodia. Sequencing an ART-sensitive F-32 Tanzania parasite line indicated artemisinin resistant K13 propeller mutations during DHA treatment in the RSA. The presence of linked-disequilibrium around genes indicated four K13 propeller mutations (Y493H, R539T, I543T, and C580Y) in the naturally-occurring parasites in Cambodia. These mutations were found associated with long parasite clearance half-life and higher frequency of survival rates in the RSA ^{0-3h}. It was also found that different levels of K13 mutations present varying levels of ART resistance, which indicate the genetic background of the parasite influencing these levels. The need for a molecular marker persists to detect and control the widespread ART resistance. Thus, it was concluded that the prevalent mutations can be utilized as markers to determine the decelerated parasite clearance rates in malarial patients receiving ART treatment. Similar studies were conducted by Ye, et al. [14] who identified the K13-propeller region of the *P. falciparum* gene as a molecular marker to detect artemisinin-resistant parasites in vitro. K13-propeller mutations are also able to identify parasitic clearance half-life (>5h) with 98.1% ART sensitivity and 88.4% host specificity.

Recent studies elaborate that the frequency of K13 mutations increase with ART usage, along with the purified selection working on the propeller region of the K-13 gene. The population of parasites unexposed to ACTs provide the fundamental information about K13-propeller gene behaving as a molecular marker of the ART resistance and elaborate a case of positive selection in the untreated propeller domain. Moreover, many contrasted K13-propeller mutations occur under ART pressure [44]. In vitro assays have determined decline in the *P. falciparum* susceptibility to ART, but no proof has yet been discovered. Feng and others accessed five mutations with three being recent. F446I mutation was predominant among the samples collected from China-Mayanmar border indicating the risks for emerging resistance in the Greater Mekong Subregion (GMS) [45]. Another molecular marker A578S was determined by Hawkes and associates in order to elaborate the genetic basis for the spread of malaria in the Ugandan Children. Being the severe case of malaria in Uganda, the nonsynonymous SNP A578S in the K13 gene may be another acknowledged marker, although not being directly associated with ART resistance, determining a delayed response and parasitic clearance rate to ART derivative [46]. Using the PCR method, DNA templates were derived from frozen samples for examination and measurement of the Plasmodium parasite by Tripura, et al. [39]. The authors related the decreased ART component drug sensitivity with the K13 propeller mutant gene (C580Y) in an attempt to prevent, treat and eliminate infections caused by *P. falciparum* and *P. vivax*.

Another breakthrough regarding the K13-propeller mutation (C580Y) has raised a concern among various studies conferring to its widespread resistance to artemisinin [39,47-51]. The C580Y is more prevalent than other ART resistant molecular markers, although it has not been observed as a consistent marker for ART resistance [33,36,37]. It is nonetheless a confirmed molecular marker of the K13

gene predominating along the Thailand-Mayanmar and Cambodia-Thailand border, while the F446I predominates along the Mayanmar-India and China-Mayanmar border [16]. Sequencing and genotyping of the PfK13 of 98 *P. falciparum* isolates in Guyana by Chenet et al. [49] determined the presence of K13 mutation (C580Y) in strong association with drug resistance. Recently, a successful study expressed K13 mutation (C580Y) in the genetically engineered clones of *P. falciparum* using the CRISPR-Cas9 system and demonstrated slow parasitic clearance rate. Through this study, direct link was established between K13 mutation and ART resistance [52].

Consequently, in a research conducted by Straimeret, et al. [17] *P. falciparum* K13 locus were genetically modified using zinc-finger nuclease and the ring-survival rates were evaluated after drug exposure in vitro. These studies suggested the decrease in the parasitic survival rates after removal of K13 mutations from ART resistant Cambodian isolates. In contrast to relevant observations, Straimer and others detected higher resistance in some K13 mutations (M476I, R493H, I543T) than other K13 mutations (Y493H and C580Y), indicating the modest resistance of C580Y being predominant mutant allele in Cambodia. Also, it suggested that additional factors were involved in augmenting K13-mediated resistance in the Cambodian isolates.

K13 POLYMORPHISM ACROSS THE GLOBE

Since the definite ART resistance phenotype is uncommon, the association of polymorphisms in marker genes is hard to relate with efficient results [53]. According to Mitaet, et al. 60 non-synonymous mutations have been identified in the K13 gene [44], while Fairhurst and Dondrop indicate that only 20 of 124 nonsynonymous K13 mutations can be associated with ART resistance (P441L, F446I, G449A, N458Y, C469Y, A481V, Y493H, S522C, G538V, R539T, I543T, P553L, R561H, V568G, P574L, C580Y, D584V, F673I, A675V, and H719N). However, only four of these have been validated in vivo and in vitro: Y493H, R539T, I543T, and C580Y [16].

Recently, Arieyet, et al. exposed the association of K13-propeller polymorphisms with ART resistance. They showed the strong relation between ART resistance and four K13-propeller polymorphisms, i.e. C580Y, Y493H, R539T, and M476L [36]. Similarly, many SNPs have been reported in K13-propeller gene along with multiple origins of the K13-propeller polymorphisms across the world, including Africa as well as Southeast Asia [53,54]. As indicated by Tanabe et al., numerous SNPs along with haplotype (3D7 sequence) exist in the four continents being geographically distinct and continent specific [55]. The fundamental information about K13-propeller gene behaving as a molecular marker of the ART resistance provided a case of positive selection in the untreated propeller domain [44].

The K13 propeller polymorphisms are known to exist widely around the world. According to a report by Edwards et al., the dispersion of malarial infection becomes widespread due to the shifting populations of higher transmission areas to lower transmission areas, which in turn retard the control and elimination of the dreadful disease by importing the infection and spreading drug resistance. Such has been demonstrated in the cross Cambodian border, the French Island of Mayotte, and China, where the malarial infections are mainly imported from other regions or transmitted locally [45,56,57].

Reports of independent global emergence of K13 mutation in a variety of locations like Mayotte (N490H, F495L, N554H/K, and

E596G) and Guyana(C580Y) have been received recently, although no information on the clinical or phenotypic resistance has been noted in these isolates [49,57]. To mark a standard for the spread of K13 polymorphisms, a novel study sequenced and genotyped 581 *P. falciparum* K13-propeller isolates from Asia, Africa, Maleneia and South America collected before and after ACT intervention. The population of isolates exposed to drugs showed higher frequencies of mutations, nucleotide and haplotype diversity as compared to the unexposed parasite population. Further indications included the prevalence of C580Y mutations earlier than that of the first report of ART resistance in 2007 [2,21,44].

A global analysis was conducted by Menard et al to map the K13-propeller polymorphisms. The authors utilized 14,037 samples from 59 countries and sequenced K13-propeller polymorphisms to evaluate the emergence and dissemination of mutations by haplotyping neighboring loci. Isolates having a similar K13 mutation were related genetically by evaluating two adjacent loci. Such phenomenon revealed the emergence of events beside the spread of mutations for ART resistance. Also, the difference of mutations and haplotypes in the two resistance regions in Asia suggested selection pressure in the relative areas due to the usage of ACTs mainly. The ratio of heterogenous nonsynonymous K13 mutations in Asia ranged from fixed to high in western Cambodia, intermediate in Myanmar and Vietnam, moderate in eastern Cambodia, Thailand, China and Laos, and low everywhere else. K13 mutations were reported uncommon in South America, Oceania and Africa except a few African nations [58]. It is however interesting to learn that the K13 polymorphisms associated with ART resistance in Southeast Asia (Y493H, R539T, I543T and C580Y) have been absent in the sub-Saharan regions and in contrast to it, the other non-synonymous SNPs identified in sub-Saharan regions have not been observed in the Southeast Asian *P. falciparum* isolates. Thus, it is proposed that the K13 polymorphisms can vary geographically and determination of K13 propeller genetic studies can reveal and monitor the global emergence of resistance to ART [34,59,60].

In relevance to the previous studies, other K13 polymorphisms were studied by Tacoli et al. Two K13 polymorphisms (P574L and A675V) are ubiquitously present in Southeast Asia and associated with decelerated clearance rate. The relevant inquiry also reports that the K13 polymorphism P574L was observed for the first time in Rwanda, suggesting their unique presence with the inclusion of strains linked to ART resistance [61]. However, the low prevalence of K13 propeller in Africa was confirmed by Torrentino-Madamet et al while identifying K13 propeller polymorphisms in the *P. falciparum* isolates collected from 29 patients receiving AL treatment on the French Island of Mayotte in 2013-2014 [57]. A study by Duru and colleagues indicated the limited genetic diversity of the parasites showing the presence of K13 polymorphisms in almost every parasite isolate from Cambodia [32]. However, the ART resistance was noted to be confined to Southeast Asia and China. Since ART-resistant K13 mutation has not been prevalent in Africa, the abundant presence of K13-propeller polymorphism A578S and others have been reported by various studies which pose serious threat to K13 propeller functioning [58,62,63].

Though it is crucial to urgently develop and implement targeted interventions to contain and eliminate ART resistance to its current locations [42], what is more alarming is the independent emergence of K13 mutations in multiple geographic locations suggesting that efforts to eliminate artemisinin-resistant malarial parasites in one

region may have a limited impact on the emergence of resistance in neighboring regions. It further highlights the need to map K13 mutations throughout the malaria-endemic world. This report is consistent in the studies determining polymorphisms in Haiti [59], Uganda [46,64,65], Angola and Mozambique [34], Rwanda [61], Kenya [66,67], Ethiopia [68, 69], Senegal [70], Mayotte [57], Southeast Asia [40], Cambodia [36], Vietnam [71], Bangladesh [72], China [51][73].

MECHANISM OF ART RESISTANCE AND K13 POLYMORPHISM

Since K13-propeller mutations are highly prognostic of resistance, the knowledge of underlying mechanisms that yields ART-resistant *P. falciparum* remains unknown [74]. It has been reported that the range of K13 mutations and development of ART resistance by single mutations point towards the declining functionality of the K13 protein. Previous research has indicated the function of human kelch-containing proteins as adapters bringing substrates into ubiquitination complexes [75]. Nonetheless, as compared to human kelch proteins (Keap 1), K13 belongs to the kelch super family of proteins, constituting of a particular Plasmodium domain and an N-terminal domain, a BTB/POZ domain and a six-blade C-terminal propeller domain made up of basic kelch motifs [76,77].

The propeller domain entertains many protein-protein sites and intercedes cellular functions like ubiquitin-regulated protein degradation and oxidative stress responses. It is suggested that the Fe-dependent generation of Reactive Oxygen Species (ROS) mediates the potential antimalarial effect of the ART and its derivatives, inducing alteration in the redox balance, and hence damages the cellular targets. It seems interesting that the toxicity of ART derivatives depends upon their pro-oxidant activity, in contrast to their involvement in the regulation of cytoprotective and protein degradation responses to outside stress [36]. However, this hypothesis further supports the evidence that K13 is highly homologous to the human Kelch protein (Keap 1), which is required in cell adaptation to oxidative stress [78]. The human kelch protein (Keap 1) is a negative regulator of the inducible cytoprotective response dependent on the nuclear erythroid 2-related factor 2 (Nrf2) [79]. The Nrf2 binds to the Antioxidant Response Element (ARE) present in the gene promoters involved in phase II detoxification and oxidative stress responses. The Nrf2 is degraded by the Keap 1, which targets it through the cullin 3 ligase complex for ubiquitination [80]. Therefore, it is presumed that the K13 propeller performs similar functions in the Plasmodium, i.e directing the transcription factors incorporated in anti-oxidant responses through ligase complex. No orthologues of Nrf2 have been determined in the parasitic genome [36]. On the contrary, many suggested hypotheses have elaborated the K13 polymorphism role in regulating artemisinin resistance in *P. falciparum* isolates.

The drug responses of Cambodian wild-type K13 and mutated samples of *P. falciparum*, Dogovski, et al. indicated the inducement of drug retardation and accumulation of ubiquitinated proteins by the ART. This action contributes to cellular stress response. The decelerated protein ubiquitination and delayed early apoptosis after drug exposure is exhibited by the resistant parasite strains, which indicates higher levels of cellular stress response. Due to its similarity to substrate adapters for cullin3 ubiquitin ligases, the role of K13 is determined in reducing the level of ubiquitinated proteins [80,81].

Furthermore, Mbengue et al. recently reported that artemisinins are potent inhibitors of *P. falciparum* phosphatidylinositol-3-kinase

(PfPI3K). PfPI3K phosphorylates Phosphatidylinositol (PI) to produce Phosphatidylinositol 3-Phosphate (PI3P) which promotes cell signaling for parasite survival, such as inhibition of apoptosis. Hence, inhibition of PfPI3K activity by DHA causes a reduction in PI3P level and subsequently leads to parasite death. They further showed that PfPI3K interacts with K13 and the K13 mutations hinder this interaction resulting in reduced polyubiquitination of PfPI3K, leading to the accumulation of PfPI3K, as well as its lipid product Phosphatidylinositol-3-Phosphate (PI3P). Thereby the authors concluded that levels of PI3P can be used as an additional marker for prediction of artemisinin resistance. But how the elevated PI3P leads to resistance needs to be further evaluated [50,65].

To elaborate the mechanism of ART further, Mok, et al. [82] emphasized the comprehensive changes of the parasite transcriptional program altering its physiology as a reason for ART resistance. Later, the authors carried out the transcriptome analyses of 1043 *P. falciparum* isolates to uncover the underlying mechanism of artemisinin resistance. They found that ART resistance was highly correlated with up-regulated genes incorporated in protein process, and since these pathways participate in Unfolded Protein Response (UPR) involving the major Plasmodium Reactive Oxidative Stress Complex (PROSC) and TCP-1 ring complex (TRiC) chaperone complexes, they may serve as the major intermediate for ART resistance caused by K13 mutation in *P. falciparum* and mitigate protein damage caused by artemisinin. It has been proposed that the K13 mutations mediate ART resistance by limiting their effects on particular targets at ring stage. Recent studies have provided evidence that the phosphatidylinositol-3-kinase (PfPI3K) of the *P. falciparum* is targeted specifically by the artemisinins and its levels are increased with K13 mutations in parasites [50]. Thus screening of K13 and PI3K proteins in Plasmodium vivax may help us extrapolate our current knowledge of drug resistance to Vivax parasites [83-85]. Another report by Wang and others proposes that the parasites with K13-propeller mutations are able to overcome protein damage due to the drug modifications by activating the stress response; thus, they are selected as they have a higher capability to survive the drug treatment at the early ring stage, at which point drug activation and drug pressure are relatively low; thereby enriching these mutations in the parasite population [33].

Other proteins have been conferred in mediating the ART resistance in the absence of K13 mutations. TRAC studies have revealed that nonsynonymous polymorphisms in multidrug-resistance protein 2, apicoplast ribosomal protein S10, chloroquine-resistance transporter (pfCRT), and ferredoxin determine the genetic background for the K13 mutations to arise [86]. It would also be important to decipher the K13-independent mechanisms of ART resistance [87-89].

The role of these proteins and pathways in artemisinin resistance is plausible, but needs further evaluation. It would be very interesting to delineate the normal function of K13 and the effect of various mutations found in the propeller domain of K13. Furthermore, it would also be interesting to decipher the identity of putative K13 targets and their association with ubiquitin ligase activity. K13-molecular targets would give the critical insight for interrogating its role in the underlying mechanism of ART resistance. Currently K13-propeller polymorphisms appear to be the only useful molecular marker for chasing the emergence and spread of ART resistance in *P. falciparum*.

CONCLUSION AND FUTURE IMPLICATIONS

The spread of malaria and the threat to the efficacy of antimalarial drugs have raised a global concern. Artemisinin has been used as a potential anti-malarial in combination with less potent drugs, but it has confronted resistance in the malaria species. The supposed ART resistance is likely to be defined as the increased rate of decelerated parasite clearance phenotype or the K13-propeller mutations, while the confirmed ART resistance delivers the slow clearing parasite phenotype along with K13 mutations associated with ART resistance [16].

K13 polymorphism has proved to be the only crucial molecular marker available for tracking the ART resistance. It may be speculated that mutations in K13 may also come with a cost to parasite fitness, and might be lost rapidly in populations in the absence of artemisinin selection. Most critical in this direction would be to determine the exact physiological roles of K13 in the parasite and the effect of these polymorphisms on its function. Very interestingly, there have been some reports of slow parasite clearance rates even in the absence of K13 mutant alleles suggesting the role of additional molecules in development of ART resistance in *P. falciparum*. It would be crucial to identify additional genetic loci involved in ART resistance [14,21,86]. Novel methodologies like GWAS [40,43], click chemistry [33], genetic tools [17,52], transcriptomics [82] and chemogenic profiling [90] can prove to be vital for solving this mystery of parasite clever escape from the currently used antimalarial drugs. Apart from understanding the current state and mechanisms of antimalarial drug resistance, it is also extremely essential to broaden understanding of this intelligent parasite [91-93] and at the same time to expand the current arsenal used against the parasite [94-97].

All in all, the artemisinin resistance still remains a gray area, about which not much is known. Strategies for regular monitoring and extensive surveillance of K13 prevalence should be implemented. The national drug policies should be viewed carefully and altered in a timely fashion according to the frequency of spreading resistance. The discovery and identification of infection phenotypes should be monitored in the malaria endemic regions and the research for the mechanism and intervention for the prevailing resistance needs to be urgently investigated.

REFERENCES

1. WHO, World Malaria Report 2014. 2014, WHO: Geneva.
2. Rick M Fairhurst, Gaurvika M L Nayyar, Joel G Breman, Rachel Hallett, Jonathan L Vennerstrom, Socheat Duong, et al. Artemisinin-resistant malaria: Research challenges, opportunities, and public health implications. *Am J Trop Med Hyg.* 2012; 87: 231-241. DOI: 10.4269/ajtmh.2012.12-0025
3. Siddiqui FA. Malaria control and elimination: How far we are: An opinion article. *J Biom Biostat.* 2016. DOI: 10.4172/2155-6180.1000321.
4. Andreas Wängdahl, Katja Wyss, Dashti Saduddin, Matteo Bottai, Elsie Ydring, Tomas Vikerfors, et al. Severity of Plasmodium falciparum and non-falciparum Malaria in travelers and migrants: A nationwide observational study over 2 decades in Sweden. *J Infect Dis.* 2019; 220: 1335-1345. DOI: 10.1093/infdis/jiz292
5. Awtum M Brashear, Wanlapa Roobsoong, Faiza A Siddiqui, Wang Nguiragool, Jetsumon Sattabongkot, Margarita M López-Urbe, et al. A glance of the blood stage transcriptome of a Southeast Asian Plasmodium ovale isolate. *PLoS Negl Trop Dis.* 2019; 13: p. e0007850. DOI: 10.1371/journal.pntd.0007850
6. Simon J Draper, Brandon K Sack, C Richter King, Carolyn M Nielsen, Julian C Rayner, Matthew K Higgins, et al. Malaria Vaccines: Recent advances and new horizons. *Cell Host Microbe.* 2018; 24: 43-56. DOI: 10.1016/j.chom.2018.06.008

7. Alok K Pandey, K Sony Reddy, Tajali Sahar, Sonal Gupta, Hina Singh, E Jyotheeswara Reddy, et al. Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies. *Infect Immun*. 2013; 81: 441-451. DOI: 10.1128/IAI.01107-12
8. Faiza Amber Siddiqui, Shikha Dhawan, Shailja Singh, Bijender Singh, Pankaj Gupta, Alok Pandey, et al. A thrombospondin structural repeat containing rho-try protein from Plasmodium falciparum mediates erythrocyte invasion. *Cell Microbiol*. 2013; 15: 1341-56. DOI: 10.1111/cmi.12118
9. Nicholas J White. Antimalarial drug resistance. *J Clin Invest*. 2004; 113: 1084-1092. DOI: 10.1172/JCI21682
10. WHO, Global Report on Antimalarial Efficacy and Drug Resistance: 2000-2010. 2010, WHO: Geneva. p. 9-10.
11. Shunmay Yeung, Wirichada Pongtavornpinyo, Ian M Hastings, Anne J Mills, Nicholas J White. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. *Am J Trop Med Hyg*. 2004; 71: 179-186. **PubMed**: <https://pubmed.ncbi.nlm.nih.gov/15331836/>
12. Klayman DL. Qinghaosu (Artemisinin): An antimalarial drug from China. *Science*. 1985; 228: 1049-1055. DOI: 10.1126/science.3887571
13. White NJ. Qinghaosu (Artemisinin): The price of success. *Science*. 2008; 320: 330-334. DOI: 10.1126/science.1155165
14. Run Ye, Dongwei Hu, Yilong Zhang, Yufu Huang, Xiaodong Sun, Jian Wang, et al. Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China-Myanmar border. *Sci Rep*. 2016; 6: 20100. DOI: 10.1038/srep20100
15. Timothy ME Davis, Harin A Karunajeewa, Kenneth F Ilett. Artemisinin-based combination therapies for uncomplicated malaria. *Med J Aust*. 2005; 182: 181-185. **PubMed**: <https://pubmed.ncbi.nlm.nih.gov/15720175/>
16. Rick M Fairhurst, Arjen M Dondorp. Artemisinin-resistant Plasmodium falciparum malaria. *Microbiol Spectr*. 2016; 4. DOI: 10.1128/microbiolspec.E110-0013-2016
17. Judith Straimer, Nina F Gnädig, Benoit Witkowski, Chanaki Amaratunga, Valentine Duru, Arba Pramundita Ramadani, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. *Science*. 2015; 347: 428-431. DOI: 10.1126/science.1260867
18. Jacob Golenser, Judith H Wankine, Miriam Krugliak, Nicholas H Hunt, Georges E Grau. Current perspectives on the mechanism of action of artemisinins. *Int J Parasitol*. 2006; 36: 1427-1441. DOI: 10.1016/j.ijpara.2006.07.011
19. Paul M O'Neill, Sarah L Rawe, Kristina Borstnik, Alison Miller, Stephen A Ward, Patrick G Bray, et al. Enantiomeric 1, 2, 4 Trioxanes display equivalent in vitro antimalarial activity versus plasmodium falciparum malaria parasites: Implications for the molecular mechanism of action of the artemisinins. *ChemBioChem*. 2005; 6: 2048-2054. DOI: 10.1002/cbic.200500048
20. Paul M O'Neill, Gary H Posner. A medicinal chemistry perspective on artemisinin and related endoperoxides. *J Med Chem*. 2004; 47: 2945-2964. DOI: 10.1021/jm030571c
21. Elizabeth A Ashley, Mehul Dhorda, Rick M Fairhurst, Chanaki Amaratunga, Parath Lim, Seila Suon, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med*. 2014; 371: 411-423. **PubMed**: <https://pubmed.ncbi.nlm.nih.gov/25075834/>
22. Amanda Hott, Debora Casandra, Kansas N Sparks, Lindsay C Morton, Geocel-Grace Castanares, Amanda Rutter, et al. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. *Antimicrob Agents Chemother*. 2015; 59: 3156-3167. DOI: 10.1128/AAC.00197-15
23. N J White, F Nosten, S Loareesuwan, W M Watkins, K Marsh, R W Snow, et al. Averting a malaria disaster. *Lancet*. 1999; 353: 1965-1967. DOI: 10.1016/S0140-6736(98)07367-x
24. L von Seidlein, S Jaffar, M Pinder, M Haywood, G Snounou, B Gemperli, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. *J Infect Dis*. 1997; 176: 1113-1116. DOI: 10.1086/516524
25. E Tjitra, S Suprianto, B J Currie, P S Morris, J R Saunders, N M Anstey. Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. *Am J Trop Med Hyg*. 2001; 65: 309-317. DOI: 10.4269/ajtmh.2001.65.309
26. M Adjuk, P Agnamey, A Babiker, S Borrmann, P Brasseur, M Cisse, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: A randomised, multicentre trial. *Lancet*. 2002; 359: 1365-1372. DOI: 10.1016/S0140-6736(02)08348-4
27. Hubert Barennes, Nicholas Nagot, Innocent Valea, Tatiana Koussoubé-Balima, Albert Ouedraogo, Thérèse Sanou, et al. A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. *Trop Med Int Health*. 2004; 9: 438-444. DOI: 10.1111/j.1365-3156.2004.01224.x
28. Sarah G Staedke, Arthur Mpimbaza, Moses R Kamya, Bridget K Nzaruaba, Grant Dorsey, Philip J Rosenthal. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: Randomised clinical trial. *Lancet*. 2004; 364: 1950-1957. DOI: 10.1016/S0140-6736(04)17478-3
29. Ghulam Rahim Awab, Mallika Imwong, Sasithon Pukrittayakamee, Fazel Alim, Warunee Hanpithakpong, Joel Tarning, et al. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: Maintained efficacy a decade after introduction. *Malar J*. 2016; 15: 121. DOI: 10.1186/s12936-016-1167-z
30. Arjen M Dondorp, François Nosten, Poravuth Yi, Debashish Das, Aung Phae Phyo, Joel Tarning, et al. Artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med*. 2009; 361: 455-467. DOI: 10.1056/NEJMoa0808859
31. WHO, Status report on artemisinin and ACT resistance - September 2015. 2015 WHO: Geneva.
32. Valentine Duru, Nimol Khim, Rithea Leang, Saorin Kim, Anais Domergue, Nimol Kloeung, et al. Plasmodium falciparum dihydroartemisinin-piperazine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperazine in vitro assays: Retrospective and prospective investigations. *BMC medicine*. 2015; 13: 1. <https://tinyurl.com/ybcqypun>
33. Zenglei Wang, Sony Shrestha, Xiaolian Li, Jun Miao, Lili Yuan, Mynthia Cabrera, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012. *Malaria journal*. 2015; 14: 1. <https://tinyurl.com/ycmlft9k>
34. Carlos Escobar, Sara Pateira, Elsa Lobo, Lis Lobo, Rosa Teodosio, Fernanda Dias, et al. Polymorphisms in Plasmodium falciparum K13-Propeller in Angola and Mozambique after the Introduction of the ACTs. *PLoS One*. 2015; 10: e0119215. DOI: 10.1371/journal.pone.0119215
35. Hui Liu, Jian-Wei Xu, Heng-Lin Yang, Mei Li, Cheng-De Sun, Yi-Jie Yin, et al. Investigation and control of a Plasmodium falciparum malaria outbreak in Shan Special Region II of Myanmar along the China-Myanmar Border from June to December 2014. *Infect Dis Poverty*. 2016; 5: 1. DOI: 10.1186/s40249-016-0127-8
36. Frédéric Arieu, Benoit Witkowski, Chanaki Amaratunga, Johann Beghain, Anne-Claire Langlois, Nimol Khim, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. *Nature*. 2014; 505: 50-55. DOI: 10.1038/nature12876
37. Kyaw Myo Tun, Aththanee Jeeyapant, Mallika Imwong, Min Thein, Sai Soe Moe Aung, Tin Maung Hlaing, et al. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: A therapeutic efficacy study. *Malaria journal*. 2016; 15: 1. <https://tinyurl.com/y9tk2zpp>
38. Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, Erika S Phelps, Kasia Stepniewska, Pharath Lim, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: A parasite clearance rate study. *Lancet Infect Dis*. 2012; 12: 851-858. DOI: 10.1016/S1473-3099(12)70181-0
39. Rupam Tripura, Thomas J Peto, Jeremy Chalk, Sue J Lee, Pasathorn Sirithiranont, Chea Nguon, et al. Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: Implications for prevention, treatment and elimination strategies. *Malaria journal*. 2016; 15: 1. <https://tinyurl.com/y986pme>
40. Shannon Takala-Harrison, Taane G Clark, Christopher G Jacob, Michael P Cummings, Olivo Miotto, Arjen M Dondorp, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. *Proc Natl Acad Sci U S A*. 2013; 110: 240-245. DOI: 10.1073/pnas.1211205110
41. Connor O'Brien, Philipp P Henrich, Neha Passi, David A Fidock. Recent

- clinical and molecular insights into emerging artemisinin resistance in *Plasmodium falciparum*. *Curr Opin Infect Dis*. 2011; 24: 570-577. DOI: 10.1097/QCO.0b013e32834cd3ed
42. Philippe Bosman, Jorgen Stassijns, Fabienne Nackers, Lydie Canier, Nimol Kim, Saorin Khim, et al. *Plasmodium* prevalence and artemisinin-resistant *falciparum* malaria in Preah Vihear Province, Cambodia: A cross-sectional population-based study. *Malar J*. 2014; 13: 394. DOI: 10.1186/1475-2875-13-394
 43. Ian H Cheeseman, Becky A Miller, Shalini Nair, Standwell Nkhoma, Asako Tan, John C Tan, et al. A major genome region underlying artemisinin resistance in malaria. *Science*. 2012; 336: 79-82. DOI: 10.1126/science.1215966
 44. Toshihiro Mita, Richard Culleton, Nobuyuki Takahashi, Masatoshi Nakamura, Takahiro Tsukahara, Carol W Hunja, et al. Little polymorphism at the K13 propeller locus in worldwide *Plasmodium falciparum* populations prior to the introduction of artemisinin combination therapies. *Antimicrob Agents Chemother*. 2016; 60: 3340-3347. DOI: 10.1128/AAC.02370-15
 45. Jun Feng, Jun Li, He Yan, Xinyu Feng, Zhigui Xia. Evaluation of antimalarial resistance marker polymorphism in returned migrant workers in china. *Antimicrob Agents Chemother*. 2015; 59: 326-330. DOI: 10.1128/AAC.04144-14
 46. Michael Hawkes, Andrea L Conroy, Robert O Opoka, Sophie Namasopo, Kathleen Zhong, W Conrad Liles, et al. Slow clearance of *Plasmodium falciparum* in severe pediatric Malaria, Uganda, 2011–2013. *Emerg Infect Dis*. 2015; 21: 1237-1239. DOI: 10.3201/eid2107.150213
 47. Whitney A Kite, Viviana A Melendez-Muniz, Roberto R Moraes Barros, Thomas E Wellems, Juliana M Sá. Alternative methods for the *Plasmodium falciparum* artemisinin ring-stage survival assay with increased simplicity and parasite stage-specificity. *Malar J*. 2016; 15: 94. DOI: 10.1186/s12936-016-1148-2
 48. Lina M Q Alareqi, Mohammed A K Mahdy, Yee-Ling Lau, Mun-Yik Fong, Rashad Abdul-Ghani, Rohela Mahmud. Molecular markers associated with resistance to commonly used antimalarial drugs among *Plasmodium falciparum* isolates from a malaria-endemic area in Taiz governorate-Yemen during the transmission season. *Acta Tropica*. 2016; 162: 174-179. <https://tinyurl.com/y7kygwos>
 49. Stella M Chenet, Sheila Akinyi Okoth, Curtis S Huber, Javin Chandrabose, Naomi W Lucchi, Eldin Talundzic, et al. Independent emergence of the *Plasmodium falciparum* kelch propeller domain mutant allele C580Y in Guyana. *J Infect Dis*. 2015; 213: 1472-1475. DOI: 10.1093/infdis/jiv752
 50. Alassane Mbengue, Souvik Bhattacharjee, Trupti Pandharkar, Haining Liu, Guillermina Estiu, Robert V Stahelin, et al. A molecular mechanism of artemisinin resistance in *Plasmodium falciparum* malaria. *Nature*. 2011; 472: 683-687. DOI: 10.1038/nature14412
 51. Jun Feng, Daili Zhou, Yingxue Lin, Huihui Xiao, He Yan, Zhigui Xia. Amplification of *pfmdr1*, *pfprt*, *pvmr1*, and K13 propeller polymorphisms associated with *Plasmodium falciparum* and *Plasmodium vivax* isolates from the China-Myanmar border. *Antimicrob Agents Chemother*. 2015; 59: 2554-2559. DOI: 10.1128/AAC.04843-14
 52. Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio JJ. Genome editing in the human malaria parasite *Plasmodium falciparum* using the CRISPR-Cas9 system. *Nat Biotechnol*. 2014; 32: 819-821. <https://tinyurl.com/y9bgjp3d>
 53. Moytre Chatterjee, Swagata Ganguly, Pabitra Saha, Biswabandhu Bankura, Nandita Basu, Madhusudan Das, et al. No polymorphism in *Plasmodium falciparum* K13 propeller gene in clinical isolates from Kolkata, India. *J Pathog*. 2015; 2015: 374354. DOI: 10.1155/2015/374354
 54. Bo Huang, Changsheng Deng, Tao Yang, Linlu Xue, Qi Wang, Shiguang Huang, et al. Polymorphisms of the artemisinin resistant marker (K13) in *Plasmodium falciparum* parasite populations of Grande Comore Island 10 years after artemisinin combination therapy. *Parasit Vectors*. 2015; 8: 634. DOI: 10.1186/s13071-015-1253-z
 55. Kazuyuki Tanabe, Sedigheh Zakeri, Nirianne Marie Q Palacpac, Manada Atsharpad, Milijaona Randrianarivelosoa, Akira Kaneko, et al. Spontaneous mutations in the *Plasmodium falciparum* sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies. *Antimicrob Agents Chemother*. 2011; 55: 94-100. DOI: 10.1128/AAC.01156-10
 56. Hannah M Edwards, Sara E Canavati, Chandary Rang, Po Ly, Siv Sovannaroeth, Lydie Canier, et al. Novel cross-border approaches to optimise identification of asymptomatic and artemisinin-resistant *Plasmodium* infection in mobile populations crossing Cambodian borders. *PLoS One*. 2015; 10: e0124300. DOI: 10.1371/journal.pone.0124300
 57. Marylin Torrentino-Madamet, Louis Collet, Jean François Lepère, Nicolas Benoit, Rémy Amalvict, Didier Ménard, et al. K13-propeller polymorphisms in *Plasmodium falciparum* isolates from patients in Mayotte in 2013 and 2014. *Antimicrob Agents Chemother*. 2015; 59: 7878-7881. DOI: 10.1128/AAC.01251-15
 58. Didier Ménard, Nimol Khim, Johann Beghain, Ayola A Adegnika, Mohammad Shafiq-Alam, Olukemi Amodu, et al. A worldwide map of *Plasmodium falciparum* K13-propeller polymorphisms. *N Engl J Med*. 2016; 374: 2453-2464. DOI: 10.1056/NEJMoa1513137
 59. Tamar E Carter, Alexis Boulter, Alexandre Existe, Jean R Romain, Jean Yves St Victor, Connie J Mulligan, et al. Artemisinin resistance-associated polymorphisms at the K13-propeller locus are absent in *Plasmodium falciparum* isolates from Haiti. *Am J Trop Med Hyg*. 2015; 92: 552-554. DOI: 10.4269/ajtmh.14-0664
 60. Faiza Amber Siddiqui, Rachasak Boonhok, Mynthia Cabrera, Huguette Gaelle Ngassa Mbenda, Meilian Wang, Hui Min, et al. Role of *Plasmodium falciparum* Kelch 13 Protein Mutations in *P. falciparum* Populations from Northeastern Myanmar in Mediating Artemisinin Resistance. *mBio*. 2020; 11: e01134-19. DOI: 10.1128/mBio.01134-19
 61. Costanza Tacoli, Prabhanjan P Gai, Claude Bayingana, Kevin Siff, Dominik Geus, Jules Ndoli, et al. Artemisinin Resistance-Associated K13 Polymorphisms of *Plasmodium falciparum* in Southern Rwanda, 2010-2015. *Am J Trop Med Hyg*. 2016; 95: 1090-1093. DOI: 10.4269/ajtmh.16-0483
 62. Steve M Taylor, Christian M Parobek, Derrick K DeConti, Kassoum Kayentao, Sheick Oumar Coulibaly, Brian M Greenwood, et al. Absence of putative artemisinin resistance mutations among *Plasmodium falciparum* in sub-Saharan Africa: a molecular epidemiologic study. *J Infect Dis*. 2015; 211: 680-688. DOI: 10.1093/infdis/jiu467
 63. Edwin Kamau, Susana Campino, Lucas Amenga-Etego, Eleanor Drury, Deus Ishengoma, Kimberly Johnson, et al. K13-propeller polymorphisms in *Plasmodium falciparum* parasites from sub-Saharan Africa. *J Infect Dis*. 2014; 211: 1352-1355. DOI: 10.1093/infdis/jiu608
 64. Roland A Cooper, Melissa D Conrad, Quentin D Watson, Stephanie J Huezio, Harriet Ninsiima, Patrick Tumwebaze, et al. Lack of artemisinin resistance in *Plasmodium falciparum* in Uganda based on parasitological and molecular assays. *Antimicrob Agents Chemother*. 2015; 59: 5061-5064. DOI: 10.1128/AAC.00921-15
 65. Melissa D Conrad, Victor Bigira, James Kapisi, Mary Muhindo, Moses R Kanya, Diane V Havlir, et al. Polymorphisms in K13 and *falcipain-2* associated with artemisinin resistance are not prevalent in *Plasmodium falciparum* isolated from Ugandan children. *PLoS One*. 2014; 9: e105690. DOI: 10.1371/journal.pone.0105690
 66. Julian Muwanguzi, Gisela Henriques, Patrick Sawa, Teun Bousema, Colin J Sutherland, Khalid B Beshir. Lack of K13 mutations in *Plasmodium falciparum* persisting after artemisinin combination therapy treatment of Kenyan children. *Malaria journal*. 2016; 15: 1. <https://tinyurl.com/y9h2aeuu>
 67. Steffen Borrmann, Judith Straimer, Leah Mwai, Abdirahman I Abdi, Njira Rippert, John Okombo, et al. Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in *Plasmodium falciparum* in Kenya. *Sci Rep*. 2013; 3: 3318. DOI: 10.1038/srep03318
 68. Abebe Genetu Bayih, Gebeyaw Getnet, Abebe Alemu, Sisay Getie, Abu Naser Mohon, Dylan R Pillai. A Unique *Plasmodium falciparum* K13 Gene Mutation in Northwest Ethiopia. *Am J Trop Med Hyg*. 2016; 94: 132-135. DOI: 10.4269/ajtmh.15-0477
 69. Alexander Heuchert, Nuredin Abduselam, Ahmed Zeynudin, Teferi Eshetu, Thomas Löscher, Andreas Wieser, et al. Molecular markers of anti-malarial drug resistance in southwest Ethiopia over time: Regional surveillance from 2006 to 2013. *Malar J*. 2015; 14: 208. DOI: 10.1186/s12936-015-0723-2
 70. Agathe Boussarrou, Bécaye Fall, Marylin Madamet, Cheikhou Camara, Nicolas Benoit, Mansour Fall, et al. Emergence of Mutations in the K13 Propeller Gene of *Plasmodium falciparum* Isolates from Dakar, Senegal, in 2013-2014. *Antimicrob Agents Chemother*. 2016; 60: 624-627. DOI: 10.1128/AAC.01346-15

71. Kamala Thriemer, Nguyen Van Hong, Anna Rosanas-Urgell, Bui Quang Phuc, Do Manh Ha, Evi Pockele, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperazine in *Plasmodium falciparum* malaria patients in central Vietnam. *Antimicrob Agents Chemother.* 2014; 58: 7049-7055. DOI: 10.1128/AAC.02746-14
72. Abu Naser Mohon, Mohammad Shafiul Alam, Abebe Genetu Bayih, Asongna Folefoc, Dea Shahinas, Rashidul Haque, et al. Mutations in *Plasmodium falciparum* K13 propeller gene from Bangladesh (2009–2013). *Malar J.* 2014; 13: 431. DOI: 10.1186/1475-2875-13-431
73. Jie Zhang, Na Li, Faiza A Siddiqui, Shiling Xu, Jinting Geng, Jiaqi Zhang, et al. In vitro susceptibility of *Plasmodium falciparum* isolates from the China-Myanmar border area to artemisinins and correlation with K13 mutations. *Int J Parasitol Drugs Drug Resist.* 2019; 10: 20-27. DOI: 10.1016/j.ijddr.2019.04.002
74. Sachel Mok, Elizabeth A Ashley, Pedro E Ferreira, Lei Zhu, Zhaoting Lin, Tomas Yeo, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. *Science.* 2015; 347: 431-435. DOI: 10.1126/science.1260403
75. Charles J Woodrow, Nicholas J White. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. *FEMS Microbiol Rev.* 2016; 41: 34-48. DOI: 10.1093/femsre/fuw037
76. J Adams, R Kelso, L Cooley. The kelch repeat superfamily of proteins: propellers of cell function. *Trends Cell Biol.* 2000; 10: 17-24. DOI: 10.1016/s0962-8924(99)01673-6
77. Soren Prag, Josephine C Adams. Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals. *BMC bioinformatics*, 2003. <https://tinyurl.com/ybpeyyvd>
78. Yoichiro Mitsuishi, Hozumi Motohashi, Masayuki Yamamoto. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. *Front Oncol.* 2011; 2: 200. DOI: 10.3389/fonc.2012.00200
79. Michaela Velichkova, Tama Hasson. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. *Mol Cell Biol.* 2005; 25: 4501-4513. DOI: 10.1128/MCB.25.11.4501-4513.2005
80. Nicole F Villeneuve, Alexandria Lau, Donna D Zhang. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases. *Antioxid Redox Signal.* 2010; 13: 1699-1712. DOI: 10.1089/ars.2010.3211
81. Con Dogovski, Stanley C Xie, Gaetan Burgio, Jess Bridgford, Sachel Mok, James M McCaw, et al. Targeting the cell stress response of *Plasmodium falciparum* to overcome artemisinin resistance. *PLoS Biol.* 2015; 13: e1002132. DOI: 10.1371/journal.pbio.1002132
82. Sachel Mok, Elizabeth A Ashley, Pedro E Ferreira, Lei Zhu, Zhaoting Lin, Tomas Yeo, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. *Science.* 2015; 347: 431-435. DOI: 10.1126/science.1260403
83. Huguette Gaelle Ngassa Mbenda, Weilin Zeng, Yao Bai, Faiza Amber Siddiqui, Zhaoqing Yang, Liwang Cui. Genetic diversity of the *Plasmodium vivax* phosphatidylinositol 3-kinase gene in two regions of the China-Myanmar border. *Infect Genet Evol.* 2018; 61: 45-52. DOI: 10.1016/j.meegid.2018.02.018
84. Huguette Gaelle Ngassa Mbenda, Meilian Wang, Jian Guo, Faiza Amber Siddiqui, Yue Hu, Zhaoqing Yang, et al. Evolution of the *Plasmodium vivax* multidrug resistance 1 gene in the Greater Mekong Subregion during malaria elimination. *Parasit Vectors.* 2020; 13: 67. DOI: 10.1186/s13071-020-3934-5
85. Meilian Wang, Faiza Amber Siddiqui, Qi Fan, Enjie Luo, Yaming Cao, Liwang Cui. Limited genetic diversity in the PvK12 Kelch protein in *Plasmodium vivax* isolates from Southeast Asia. *Malar J.* 2016; 15: 537. DOI: 10.1186/s12936-016-1583-0
86. Olivo Miotto, Roberto Amato, Elizabeth A Ashley, Bronwyn MacInnis, Jacob Almagro-Garcia, Chanaki Amaratunga, et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet.* 2015; 47: 226-234. DOI: 10.1038/ng.3189
87. Angana Mukherjee, Selina Bopp, Pamela Magistrado, Wesley Wong, Rachel Daniels, Allison Demas, et al. Artemisinin resistance without pfkelch13 mutations in *Plasmodium falciparum* isolates from Cambodia. *Malar J.* 2017; 16: 195. DOI: 10.1186/s12936-017-1845-5
88. Faiza A Siddiqui, Mynthia Cabrera, Meilian Wang, Awtum Brashear, Karen Kemirembe, Zenglei Wang, et al. *Plasmodium falciparum* Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance. *J Infect Dis.* 2018; 218: 434-442. DOI: 10.1093/infdis/jiy188
89. Yan Zhao, Ziling Liu, Myat Thu Soe, Lin Wang, Than Naing Soe, Huanping Wei, et al. Genetic Variations Associated with Drug Resistance Markers in Asymptomatic *Plasmodium falciparum* Infections in Myanmar. *Genes (Basel).* 2019; 10: 692. DOI: 10.3390/genes10090692
90. Anupam Pradhan, Geoffrey H Siwo, Naresh Singh, Brian Martens, Bharath Balu, Katrina A Button-Simons, et al. Chemogenomic profiling of *Plasmodium falciparum* as a tool to aid antimalarial drug discovery. *Scientific reports.* 2015. <https://tinyurl.com/y9ur6dml>
91. Mahmood M Alam, Lev Solyakov, Andrew R Bottrill, Christian Flueck, Faiza A Siddiqui, Shailja Singh, et al. Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion. *Nat Commun.* 2015; 6: 7285. DOI: 10.1038/ncomms8285
92. Amrita Dawn, Shailja Singh, Kunal R More, Faiza Amber Siddiqui, Niseema Pachikara, Ghania Ramdani, et al. The central role of cAMP in regulating *Plasmodium falciparum* merozoite invasion of human erythrocytes. *PLoS Pathog.* 2014; 10: e1004520. DOI: 10.1371/journal.ppat.1004520
93. Xiaoying Liang, Kevin J Hart, Gang Dong, Faiza A Siddiqui, Aswathy Sebastian, Xiaolian Li, et al. Puf3 participates in ribosomal biogenesis in malaria parasites. *J Cell Sci.* 2018; 131: jcs212597. DOI: 10.1242/jcs.212597
94. Jared N Balaich, Derrick K Mathias, Baldwyn Torto, Bryan T Jackson, Dingyin Tao, Babak Ebrahimi, et al. The Nonartemisinin Sesquiterpene Lactones Parthenin and Parthenolide Block *Plasmodium falciparum* Sexual Stage Transmission. *Antimicrob Agents Chemother.* 2016; 60: 2108-2117. DOI: 10.1128/AAC.02002-15
95. Bryan T Mott, Richard T Eastman, Rajarshi Guha, Katy S Sherlach, Amila Siriwardana, Paul Shinn, et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. *Sci Rep.* 2015; 5: 13891. DOI: 10.1038/srep13891
96. Beatriz Baragaña, Irene Hallyburton, Marcus C S Lee, Neil R Norcross, Raffaella Grimaldi, Thomas D Otto, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. *Nature.* 2015; 522: 315-320. DOI: 10.1038/nature14451
97. Santanu Hati, Sanjay M Madurkar, Chandramohan Bathula, Chiranjeevi Thulluri, Rahul Agarwal, Faiza Amber Siddiqui, et al. Design, synthesis and biological evaluation of small molecules as potent glucosidase inhibitors. *Eur J Med Chem.* 2015; 100: 188-196. DOI: 10.1016/j.ejmech.2015.04.059